Directory · US
Biotechnology Research in United States
A register of firms and the professionals working at them in the Biotechnology Research sector based in United States. Browse the public index, then filter or export on Kipplo.
Companies
12K on file
Thomas Scientific
Thomas Scientifics’ guiding principle is “We Believe You Are Important” and this belief guides our every action and investment. We have been delivering quality laboratory supplies and scientific equipment to the worldwide scientific market since 1900. We are a full-line stocking distributor and have developed a broad portfolio of products to support your operational needs, including: Supplies and Consumables, Equipment, Instruments and Furniture, Chemicals and Reagents, as well as Laboratory and Facility Safety and Apparel. Thomas Scientific operates as a classic distributor with a robust sales team to fully support your needs, as well as an online procurement operation in North America and Internationally for Laboratory Supplies and Consumables, Equipment, Instruments and Furniture, Chemicals, and Laboratory Safety and Apparel. Our website, ThomasSci.com, operates as a wholesale and retail Website. Thomas Scientific serves Science through ThomasSci.com and focuses on selection, price, and convenience.
51 to 200 staff
Total Validation Services
Total Validation Services (TVS) is an industry leader in delivering practical and cost-effective commissioning, qualification, and validation solutions, in addition to project management and quality consulting services, to the pharmaceutical, biotechnology, and medical device industries. Our Vision:"To partner with our clients to make a difference in lives around the world" Our MIssion:"TVS strives to be an industry leader in developing and delivering high quality, value-added validation services."
11 to 50 staff
Trans Ova Genetics
Trans Ova Genetics provides industry-leading reproductive technologies and expertise to cattle breeders through a unique professional services team that works closely with clients to understand their breeding goals, and ultimately help clients advance and extend superior genetics. Trans Ova Genetics understands the process that will help multiply a herd’s genetic success. Reproductive technologies such as embryo transfer, in-vitro fertilization (IVF), sexed-semen, genetic preservation and cloning are considered the reproductive “tools” available for breeders looking to achieve specific breeding and reproductive goals. Internationally recognized as a source of superior animal husbandry and reproductive expertise, Trans Ova Genetics offers an integrated system of regional centers, satellite stations and on-farm application of reproductive technologies. From veterinarians and embryologists, to animal caretakers and client service representatives, each location and its team share a consistent commitment to client service that can multiply the results within any breeding program. On-going research and applied science allows Trans Ova Genetics to develop and implement new technologies that will help move the science of bovine genetic improvement forward. Trans Ova is dedicated to meeting the requirements of their customers and to continual improvement.
201 to 500 staff
Truvian
Our mission is to provide unprecedented access to blood testing. We enable sustainable healthcare with accessible blood testing for a healthier you.
51 to 200 staff
Twist Bioscience
Twist Bioscience is a synthetic biology company based in South San Francisco, California. The company has developed a proprietary silicon-based manufacturing process for the production of synthetic DNA. Twist Bioscience serves Life Science researchers who are changing the world for the better. Coming from diverse fields of medicine, agriculture, and industrial chemicals, scientists use our synthetic genes, oligo pools, biopharma services, and NGS target enrichment to better lives and improve the sustainability of the planet. Twist Bioscience is uniquely positioned to help accelerate these efforts by providing precision at a scale that is otherwise unavailable. Our technology overcomes inefficiencies and enables cost-effective, rapid, precise, high-throughput DNA synthesis and sequencing. We offer both the quality and quantity researchers need now to rapidly realize opportunities ahead. Twitter @TwistBioscience Facebook facebook.com/TwistBioscience YouTube youtube.com/TwistBioscience #WeMakeDNA
501 to 1000 staff
Vaxart, Inc
For two hundred years vaccines have been administered by intramuscular injection. Vaxart’s oral vaccine pills may change everything. Our vaccine pills act differently, by attacking invading pathogens in the places where they first enter the body: the mucosal areas, including the mouth, the nose and the gut. They are designed to trigger strong IgA and T-cell responses to repel and overwhelm the invading viral invaders. Vaxart has begun Phase II trials of its oral vaccine for Covid and for Norovirus– the only company in the world to reach this stage with a COVID-19 vaccine pill.
51 to 200 staff
Velocity Clinical Research, Inc
Velocity is the world’s leading organization of fully integrated clinical research sites. With 70+ sites and 200+ investigators, Velocity partners with pharmaceutical and biotechnology companies to research new drugs, medical devices, diagnostics, and combination products that could improve human health and wellbeing. Velocity offers unified research site solutions to efficiently provide the right patients, investigators, and research staff for clinical trials across the U.S. and Europe. The company also operates a technology hub in India, where it is unlocking a new era in clinical research by developing innovative systems to leverage expansive site, patient, and historical performance data. To learn more about how Velocity delivers high-quality data, exemplary patient care, and unprecedented efficiency for clinical trials at any scale, visit VelocityClinical.com.
1001 to 5000 staff
Verastem Oncology
Verastem Oncology (Nasdaq: VSTM)(Verastem, Inc.) is a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition and KRAS G12D inhibition. Pursuing unexplored pathways demands that we’re purposeful in everything we do. And it’s an endeavor that’s only possible with an experienced team of employees and partners dedicated to a singular purpose: changing and improving the way cancer is treated by delivering novel therapies that address areas of high unmet need in RAS/MAPK pathway-driven cancers. At Verastem Oncology, it takes our diversity of backgrounds, expertise, perspectives, and skills to find the answers that patients need, but don’t have—yet. To join our team or for more information, please visit X/Twitter:@VerastemOncolog
51 to 200 staff
Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. We currently market two autologous cell therapy products and one specialty biologic product in the United States. Personal integrity, teamwork, collaboration, and innovative technology are the foundations of our work. We seek to practice transparency in our clinical trials and research, and in our relationships with each other, our patients, and the investors who support us. PRIVACY AND COMMUNITY GUIDELINES When you engage with Vericel social media channels and our content providers on social media, you also agree to abide by the following Community Guidelines (found here: https://bit.ly/3pg3UKQ), which apply in addition to the Terms and Conditions or other legal notices specific to each social media channel. Please note that third-party social media channels also have access to information you share via social media. For more details, read LinkedIn's Privacy Policy here: https://bit.ly/3GF2r5Y. For additional information about privacy at Vericel, please see our Privacy Policy (bit.ly/43ErZcx) and Terms and Conditions of Use (bit.ly/4568Cdx). If you engage with us, you consent and give Vericel permission to communicate with you and to use any information, text and media associated with the interaction or post.
201 to 500 staff
Vgxi
VGXI is a leading-edge CDMO dedicated to revolutionizing the biopharmaceutical industry with best-in-class nucleic acid-based products and services. We deliver manufacturing excellence in state-of-the-art facilities with the agility and scale to meet projects of all sizes to serve the global community of next-generation therapeutic developers.
51 to 200 staff
Vytelle
Vytelle is a data enabled biotechnology company reshaping how cattle producers worldwide optimize their herds. Through Vytelle’s integrated technology platform, generations of genetic gains can be made in just a few years. This allows producers to sustainably deliver more protein with fewer inputs, helping to ensure meat and milk are viable, competitive food choices for future generations.
51 to 200 staff
Wave Life Sciences
We are a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Our RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Our toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Our diversified pipeline includes clinical programs in Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease, and obesity, as well as several preclinical programs utilizing our broad RNA therapeutics toolkit. Driven by the calling to “Reimagine Possible”, we are leading the charge toward a world in which human potential is no longer hindered by the burden of disease.
201 to 500 staff
Zeptometrix
ZeptoMetrix brings together some of the world's leading scientists in the fight against infectious disease. We are proud to offer an extensive range of research products and services that are continuously expanding. Our Mission “Partner to our Customer” is the basis for our successful collaboration with scientists across the globe.
51 to 200 staff
Zymo Research Corp
Since its inception in 1994, Zymo Research has been proudly serving the scientific community by providing innovative, reliable, and high quality research tools at affordable prices. Our vision."The Beauty of Science is to Make Things Simple" is now truer than ever. Whether it's epigenetics, DNA, RNA, E. coli, or yeast based research, our philosophy remains the same: To provide the highest quality products in the industry while ensuring they are both simple to use and reliable in their performance. Zymo Research is historically recognized for its innovation of high quality nucleic acid purification technologies. Under the branding DNA Purification Made Simple™ and RNA Purification Made Simple™, our technologies are pushing the limits of what is possible with nucleic acid isolation. As The Epigenetics Company™, Zymo Research has also received much attention for its rapidly expanding portfolio of epigenetics products and services. It is our objective to develop and provide the most comprehensive set of tools for DNA, RNA, and epigenetic research and analysis available today. Thousands of peer-reviewed scientific publications from researchers around the world feature our technologies. Through innovation, our scientists have made streamlined DNA methylation detection possible, pioneered the micro-elution column for DNA and RNA purification, developed the simplest and the most sophisticated methods for high-quality plasmid DNA purification, and patented the first RNA purification directly from Trizol without phase separation among many other leading technologies in the industry. At Zymo Research, we are committed to quality and guarantee that all of our products and service will meet and exceed your expectations. We pledge to be honest and responsible for everything we do with you. We will treat you as we would like to be treated. Together, we will build a brighter future.
201 to 500 staff
Agrinos
Agrinos, An American Vanguard Company, is a biological crop input provider committed to improving the productivity and sustainability of modern agriculture worldwide. Our products help farmers by providing increased crop yield and productivity, improved crop quality, enhanced efficiency of conventional fertilizer and a reduced environmental footprint. As world population grows rapidly and natural resources become increasingly strained, we need innovative, sustainable solutions that increase agricultural output, reduce inputs and ensure a safe, reliable food supply for all. As a worldwide leader in crop biologicals, Agrinos is proud to help meet that challenge. Agrinos products, developed through our proprietary High Yield Technology (HYT®) platform, have pioneered the quickly growing crop biologicals sector and have been proven to drive yield and quality improvements across diverse crops and environments across the globe. Agrinos’ global research, development and agronomy team is creating innovative products at the forefront of microbial and biological crop input innovation to improve the productivity and sustainability of today’s farmer. We deliver innovative products to improve the health of the soil microbiome—the critical foundation required for crops to reach their full potential—and ultimately bring prosperity to the grower. Groundbreaking innovation that enriches the soil microbiome is helping to shape the potential of modern agriculture—and Agrinos is a leader in delivering on that potential.
51 to 200 staff
Alamar Biosciences, Inc
Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. Our proprietary NULISA™ Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. The NULISAseq Inflammation Panel contains 200+ important markers related to immune and inflammatory diseases and will run on our ARGO™ System. This innovative platform allows for a fully automated workflow with less than 30 minutes hands on time from sample to data.
51 to 200 staff
Andelyn Biosciences
Andelyn Biosciences is a gene therapy CDMO dedicated to Turning Hope Into Reality™. Founded out of Nationwide Children’s Hospital, we support the development and manufacturing of innovative cell and gene therapies with a deep sense of responsibility to our partners and the patients and families behind the science. With more than 20 years of experience in viral vector manufacturing, Andelyn offers clients access to deep scientific expertise and globally recognized thought leadership. We have produced GMP material for more than 75 worldwide clinical trials, over 450 cGMP clinical batches, and more than research-grade productions. Our capabilities span viral vector process and analytical development, adherent and suspension-based GMP drug substance manufacturing up to GMP plasmid process development and manufacturing, advanced quality systems, and integrated supply chain capabilities. Located in Columbus, Ohio, our clinical and commercial manufacturing facility supports programs from clinical through commercial scale, helping accelerate the delivery of therapies to patients who need them.
201 to 500 staff
Annexon Biosciences
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. The company’s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio. For more information, visit
51 to 200 staff
Armata Pharmaceuticals, Inc
Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing. More information is available at
51 to 200 staff
Aspen Neuroscience, Inc
Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for Parkinson’s disease (PD) and extending across the brain and affected organs.
51 to 200 staff
Assembly Biosciences, Inc
Assembly Biosciences is a biotechnology company dedicated to the development of innovative small molecule antiviral therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Led by an accomplished team of leaders in virologic drug development, Assembly Bio is committed to improving outcomes for patients struggling with the serious, chronic impacts of herpesvirus, hepatitis B virus (HBV) and hepatitis delta virus (HDV) infections. For more information, visit assemblybio.com. Assembly is headquartered in South San Francisco.
51 to 200 staff
Avance Clinical
Avance Clinical is a full-service Contract Research Organization (CRO) headquartered in Australia, with extensive operations across New Zealand, Asia, North America, and Europe. As the market leaders in early phase clinical trials, we leverage the unique advantages of the Australian market, including rapid ethics approval, no IND requirement, and the 43.5% R&D tax rebate, to provide biotechs with an accelerated pathway to clinical success. Specializing in world-class operations, we guide biotechs from early pre-clinical development through to late-phase studies. With a focus on agility, innovation, and cost-effectiveness, we deliver fast results backed by robust, globally accepted data. With expertise spanning over 250+ indications, across all therapeutic areas, over the last three decades, Avance Clinical consistently delivers data recognized by key global regulators, including the TGA, FDA, EMA, MHRA, MFDS, and PDMA. What sets us apart is our personalized service tailored to each client, ensuring customized, flexible solutions rather than a one-size-fits-all approach.
201 to 500 staff
Bioconsortia, Inc
BioConsortia, Inc. is revolutionizing agriculture with cutting-edge microbial solutions that boost plant health, increase yields, and promote sustainability. As leaders in gene editing and directed selection of microbes, BioConsortia harnesses the power of robust, spore-forming bacteria to develop innovative seed treatments and foliar products. The company’s proprietary Advanced Microbial Selection (AMS) process and GenePro genomics platform enable BioConsortia scientists to identify, design, and enhance microbes that help unlock the full potential of crop plants. From nitrogen-fixing microbes that reduce reliance on synthetic fertilizers to biopesticides and biostimulants that protect crops and improve resilience, BioConsortia delivers consistent, effective products that benefit growers and the environment.
11 to 50 staff
Biotissue
BioTissue is the leader in innovative technologies using products derived from human amniotic and umbilical cord tissues. Since its inception in 1997, the Company has pioneered the clinical application of human placental tissues – more than patients have been treated with BioTissue products and the Company’s groundbreaking scientific and clinical achievements have been documented in more than 380 peer-reviewed publications.
201 to 500 staff
Brainco Inc
BrainCo’s leadership draws on deep experience in neuroscience research and expertise in education to deliver entirely new applications of brainwave technology in the education, wellness, and research spaces. We’ve learned important lessons as we’ve grown from a small team in an apartment basement to over 100 employees in 4 offices around the world. Since 2015 we’ve been working on providing the best experience possible for our customers and we’re here to share our progress and innovations with you.
51 to 200 staff
Bruker Microbiology & Infection Diagnostics
We are driven by the idea to support researchers, laboratories and healthcare providers in the rapid identification and analysis of microorganisms. With Bruker’s innovative Microbiology & Diagnostic solutions we serve the needs of our customers with instruments and assays that meet the demand of clinical microbiologists and those in industrial and applied microbiology. To help understanding how microbes cause disease and evade treatment we offer a range of products that extends from antimicrobial susceptibility testing, microbial identification and strain typing to molecular diagnostics as well as sepsis and resistance testing. Privacy Policy: Imprint: Bruker Daltonics GmbH & Co. KG Fahrenheitstr. 4 28359 Bremen
201 to 500 staff
Calibre Scientific
Calibre Scientific is a diversified global provider of life science reagents, tools, instruments, and other consumables to the lab research, diagnostics and biopharmaceutical communities. The Company is committed to pushing the boundaries of science and innovation through internal expertise combined with strategic acquisitions that help deliver a differentiated and comprehensive set of products, services and support to our customers. Calibre Scientific was founded in 2016 by assembling a portfolio of niche life science companies, across various key verticals, that have an unrivaled ability to address the unique challenges of their respective markets. Through a combination of acquisitions and organic growth, our global reach extends into over 175 countries, empowering customers all over the world. Headquartered in Holland, Ohio, Calibre Scientific continues to grow across a wide array of verticals and geographies, further diversifying its product offering and global footprint to laboratories around the world.
1001 to 5000 staff
Charter Medical
Lifechanging breakthroughs like cell and gene therapy are driving a medical revolution. But a lack of purpose-built development and manufacturing tools keeps these treatments from reaching more patients. At Charter Medical, we’re on a mission to evolve single-use cell processing step-by-step with the needs of the biopharmaceutical innovators who count on us. With proven customization capabilities and an innovation roadmap that includes pioneering design and biomaterials. With industry-leading expertise and continuous improvement to simplify and standardize biomanufacturing systems so they can scale reliably. And with a deep commitment to responsiveness, collaboration and urgency. Because we know single-use advances are essential to helping our clients make revolutionary therapies more accessible to patients who need them – now.
51 to 200 staff
Crystal Pharmatech
Crystal Pharmatech – From Solid Form to Clinical Formulation, Right the First Time Founded in 2010, Crystal Pharmatech is a global leader in solid form and formulation science, dedicated to transforming molecules into medicines right the first time. With over clients and more than compounds supported, we bring unmatched expertise across solid-state research, crystallization, pre-formulation, formulation development, and manufacturing. Operating from four R&D centers in New Jersey, California, Toronto, and Suzhou, our 300-member team delivers integrated solutions powered by science, precision, and collaboration. Our cGMP facilities meet FDA, EMA, and NMPA standards, ensuring global quality and compliance. As a pioneer in enabling formulation technologies — including amorphous solid dispersion — we streamline development from developability assessment to clinical trial manufacturing (CTM) and commercial scale-up. Our signature Mol2Med™ Program accelerates small-molecule candidates from lead optimization or preclinical candidate (PCC) stage to Phase I and beyond through a proven three-step, First-Time-Right approach: Step 1: Developability Assessment – Guiding API form selection and formulation design. Step 2: Solid Form Screening & Preformulation – Ensuring stability and performance. Step 3: Formulation Development & CTM Manufacturing – Including packaging, labeling, and clinical-site delivery. This integrated pathway ensures a robust API form, scalable process, and a First-Time-Right formulation that sets the foundation for seamless advancement into future clinical phases.
201 to 500 staff
Curis
Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development of first-in-class and innovative therapeutics or the treatment of cancer. The Company currently has three drug candidates in development- Emavusertib (CA-4948), an orally-available, small molecule inhibitor of the IRAK4 kinase being investigated in a Phase 1 clinical trial in patients with non-Hodgkin's lymphoma and in a separate Phase 1 trial for acute myeloid leukemia and myelodysplastic syndromes- Fimepinostat, an orally available, small molecule inhibitor of HDAC and PI3K enzymes, which is currently being evaluated for future studies. Curis is engaged in a collaboration with Aurigene for discovery and development of drug candidates in the area of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule dual antagonists of PD1 and TIM3, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. The Company's collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc, or Genentech, a member of the Roche Group, are commercializing Erivedge®(vismodegib) for the treatment of patients with advanced basal cell carcinoma, or BCC. We are seeking dedicated, driven, humble, hands-on professionals, from diverse backgrounds, who are passionate about making a difference in the lives of patients and families touched by cancer, and who want to have some fun while doing it. For more information, visit Curis's website at
11 to 50 staff
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a commercial-stage company that believes when it comes to pediatric cancer, we can do better. Day One was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Inspired by “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan, Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One. Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important targeted cancer treatments. The Company’s pipeline includes tovorafenib (OJEMDA™) and DAY301.
51 to 200 staff
Dragonfly Therapeutics, Inc
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel multispecific antibody technology to harness the body's immune system to bring breakthrough treatments to patients. In addition to its wholly owned clinical assets, Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platform, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas. For more information, email info@dragonflytx.com.
51 to 200 staff
Editas Medicine
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
201 to 500 staff
Element Biosciences
Element Biosciences is a life science company democratizing access to advanced biological tools, driving impactful discoveries to benefit humanity. Through innovating every fundamental element of a biological assay system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries.
201 to 500 staff
Elevatebio
ElevateBio is a technology-driven company built to power transformative genetic medicines today and for many decades to come. The Company commercializes its enabling technologies, manufacturing capabilities, and industry-leading expertise through partnerships to accelerate development across a breadth of therapeutic approaches and modalities. The ElevateBio ecosystem combines Life Edit, its gene editing technologies and R&D business, with BaseCamp®, its end-to-end genetic medicine process development and cGMP manufacturing business, to accelerate the discovery and development of advanced therapeutics. ElevateBio aims to be the dominant engine inside the world’s greatest scientific advancements harnessing human cells and genes to alter disease.
201 to 500 staff
Encoded Therapeutics Inc
Encoded Therapeutics is creating one-time, disease-modifying gene therapies for pediatric central nervous system (CNS) disorders with its cell-selective targeting and regulation platform. The Encoded approach offers potentially unprecedented gene specificity and cell selectivity to unlock novel opportunities by targeting a range of disease mechanisms. Encoded’s technology is compatible with any delivery system to control where and when therapeutic transgenes are expressed, thereby shaping the functionality of target cells and holding broader therapeutic potential beyond CNS disorders. For more information, please visit and follow us on LinkedIn, Twitter @EncodedTx and YouTube. Social media guidelines: https://encoded.com/social-media-community-guidelines/
51 to 200 staff
Engene
enGene (Nasdaq: ENGN) is a clinical-stage biotechnology company mainstreaming non-viral genetic medicines that can be delivered locally to the site of disease—starting with non-muscle invasive bladder cancer (NMIBC) and expanding beyond. Founded in Canada, with a United States headquarters located in Boston, we are developing innovative solutions with the goal of reducing treatment burden and improving patient outcomes. To learn more about enGene visit our website: enGene.com. We are currently enrolling select patients with NMIBC in our LEGEND clinical trial. We have sites in the United States, Canada, Europe and the Asia-Pacific region. For more information, please visit TheLegendStudy.com.
11 to 50 staff
Epicypher, Inc
A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers world-wide. Our technologies and products are making studies possible that were not imaginable just a few years ago. Our renowned chromatin researchers possess expertise and unique insight into chromatin biology and drug discovery that benefit our customers in ways other companies cannot. Epigenetics, the study of changes in heritable traits that occur independent of alterations in changes in the underlying DNA sequence, is an emerging and important area of biomedical research with broad impact on human health and disease.
11 to 50 staff
Eurofins Discoverx
Eurofins DiscoverX, the products company of Eurofins Discovery, is committed to enabling and accelerating multi-modality drug discovery and development from discovery to QC lot release. For drug discovery and development scientists, Eurofins DiscoverX is the trusted product solutions provider that accelerates research and drug discovery programs with confidence for cytokine receptors, checkpoint receptors, GPCRs, kinases, ion channels, epigenetics, nuclear receptors, and other target families. Eurofins DiscoverX develops and manufactures cutting edge assays, stable cell lines, ready-to-use kits (including bioassays), membrane preps, enzymes, and reagents for small molecule and biologic immuno-oncology, cytotoxicity, compound-target engagement, potency and QC lot release, pharmacotrafficking, and many other applications. These products are developed from 3 R&D and manufacturing centers of excellence – San Francisco Bay Area California (Fremont); St. Louis area, Missouri (St. Charles); and Poitiers, France.
51 to 200 staff
Evenly Technologies
Evenly is Orthodontics in-a-box for dentists. We are the nation’s largest and fastest growing outsourced Orthodontic solution for dental offices. Headquartered in Washington D.C, Evenly is backed by the world’s leading venture capital investors.
51 to 200 staff
Flagship Biosciences, Inc
Founded in 2009, Flagship Biosciences, Inc, is a technology-driven spatial biology and biomarker services company delivering the most accurate and informative data available. We are revolutionizing biomarker analysis to improve drug development and diagnostics using the power of AI with a consultative approach. Our services and technology dramatically improve on the data and interpretation from traditional methods, eliminating variability associated with typical biomarker assessments, and bringing new insights to analysis results. We provide expert scientific consultation for every client. Our team interprets results, contextualizes biology, and identifies the best course for success.
51 to 200 staff
Forge Biologics
Forge, a member of Ajinomoto Bio-Pharma Services, is a gene therapy development engine, focused on enabling access to life changing gene therapies and helping bring them from idea into reality. We partner with innovators in the gene therapy community: scientists, physicians, biotech/pharma companies, and patient groups. We bring expertise in gene therapy manufacturing and therapeutics development to the table, helping champion teams that are navigating the long road from the lab bench to the bedside. With a patients-first approach, we are forging new models for working together to better accelerate these transformative medicines to reach those who need them most.
201 to 500 staff
Fujifilm Cellular Dynamics, Inc
Fujifilm Cellular Dynamics, Inc. develops and manufactures biologically relevant human cells derived from induced pluripotent stem (iPS) cells. Our iCell® and donor-specific MyCell® Products are highly pure, highly reproducible, and available in industrial quantity to enable drug discovery, toxicity testing, stem cell banking, and cell therapy development.
51 to 200 staff
Fulcrum Therapeutics
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases. Community Guidelines: https://bit.ly/3t2xeR9
51 to 200 staff
Ginkgo Bioworks, Inc
At Ginkgo, we use biology to grow the future. Companies across industries leverage our platform to design, develop, and optimize products for a breadth of commercial applications. We help our partners grow key ingredients for vaccines, crops that rely less on fossil fuel-based fertilizers, plant-based meat that tastes like the real thing, materials for the next generation of circular fashion, and so much more. We know our unique experiences, ideas, and perspectives are essential to our success and enable us to make biology easier to engineer and ensure equitable distribution of the benefits of our platform. As such, we seek to to grow an inclusive culture and diverse workforce. Let's make biology easier to engineer and join our team.
501 to 1000 staff
Harlan Laboratories, Inc
Harlan Laboratories, Inc. was founded in 1931. In September 2015, Harlan merged with Huntingdon Life Sciences to form Envigo. This new organization provides essential products and research services for biopharmaceutical, crop protection, and chemical companies as well as universities, governments, and other research organizations. For company news, career opportunities and information about available products and services, follow Envigo's LinkedIn page at
1001 to 5000 staff
Holganix
Holganix and the American Farmer are revolutionizing the way we grow crops, restoring life to the soil to make it healthier and ensure Thrivability for all. At Holganix, we’re out to prove that what’s good for the soil is good for the farmer—and good for the Earth. We’re pioneering a practical, science-backed approach to regenerative ag that boosts soil biology, strengthens productivity, and helps farmers reduce reliance on synthetic inputs—without sacrificing yield or profit. At the heart of it all is Bio 800+, our flagship microbial powerhouse packed with over 800 naturally occurring soil microbes. It’s like a probiotic for your soil: rebuilding structure, improving nutrient and water efficiency, and taking carbon from the air and placed at a plant's roots, where it does the most good. Restoring soil health across America means better crops with bigger yields; fewer chemicals; lower farm costs; stronger water retention; and less erosion. But it’s not just bugs in a jug. We pair Bio 800 with best-in-class data—soil testing, satellite imagery, and machine-level farm insights—to help farmers and landowners shift toward regenerative practices that are built for scale, backed by verification, and designed for long-term impact. Whether you're a farmer looking to build healthier soils, or a corporate partner aiming for carbon insets and transparent carbon accounting, we're here to help regenerate soils, rural economies, and the Earth —all at once.
51 to 200 staff
Icosagen
Icosagen is a unique European CRDMO, being successfully in the business for more than 25 years as an independent family-owned company. As such, we combine pre-clinical CRO and clinical CDMO development expertise at one single site for therapeutic antibodies, multispecifics, ADCs, and other complex recombinant protein drug candidates. As a CRDMO we discover, develop, and manufacture proteins seamlessly from research concepts into pre-clinical and clinical development stages. This includes everything from small-scale transient productions to stable high producing cell lines, to manufacture clinical GMP materials in our modern GMP facility. In 2024, we continued our partnership with over 100 biotech & pharma companies on 500 projects, producing more than different proteins.
201 to 500 staff
